Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis

Zoltán H Endre; John W Pickering

doi:10.1038/nrneph.2014.198

Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis

Nat Rev Nephrol. 2014 Dec;10(12):683-5. doi: 10.1038/nrneph.2014.198. Epub 2014 Oct 28.

Authors

Zoltán H Endre¹, John W Pickering²

Affiliations

¹ Department of Nephrology, Prince of Wales Hospital and Clinical School, University of New South Wales, High Street, Randwick, Sydney, NSW 2031, Australia.
² Department of Medicine, University of Otago-Christchurch, and the Emergency Care Foundation, Christchurch Hospital, Riccarton Avenue, Christchurch 8140, New Zealand.

PMID: 25347946
DOI: 10.1038/nrneph.2014.198

Abstract

FDA approval of the first device to use novel biomarkers of kidney damage to assess risk of acute kidney injury (AKI) potentially brings forward diagnosis of moderate-to-severe AKI to a time frame that could enable early intervention. Although the device awaits greater scrutiny, its approval marks the beginning of a new era.

MeSH terms

Acute Kidney Injury / diagnosis*
Acute Kidney Injury / pathology
Acute Kidney Injury / prevention & control
Acute Kidney Injury / urine*
Biomarkers / urine
Cell Cycle Checkpoints*
Early Diagnosis*
Female
Fluoroimmunoassay / methods
Humans
Insulin-Like Growth Factor Binding Proteins / urine*
Male
Matrix Metalloproteinase 2 / urine*
Point-of-Care Systems
Sensitivity and Specificity
United States
United States Food and Drug Administration

Substances

Biomarkers
Insulin-Like Growth Factor Binding Proteins
Matrix Metalloproteinase 2